Proautophagic Drugs: A Novel Means to Combat Apoptosis-Resistant Cancers, with a Special Emphasis on Glioblastomas

Viktorsson, 2005, Apoptotic pathways and therapy resistance in human malignancies, Adv Cancer Res, 94, 143, 10.1016/S0065-230X(05)94004-9

Ricci, 2006, Chemotherapeutic approaches for targeting cell death pathways, The Oncologist, 11, 342, 10.1634/theoncologist.11-4-342

Okada, 2004, Pathways of apoptotic and non-apoptotic death in tumour cells, Nat Rev Cancer, 4, 592, 10.1038/nrc1412

Fesik, 2005, Promoting apoptosis as a strategy for cancer drug discovery, Nat Rev Cancer, 5, 876, 10.1038/nrc1736

McCarthy, 2007, Therapy: Inhibiting the inhibitors, Nat Rev Cancer, 7, 5, 10.1038/nrc2052

Bedikian, 2006, Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group, J Clin Oncol, 24, 4738, 10.1200/JCO.2006.06.0483

Tolcher, 2005, A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer, Clin Cancer Res, 11, 3854, 10.1158/1078-0432.CCR-04-2145

Rowinsky, 2005, Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents, J Clin Oncol, 23, 9394, 10.1200/JCO.2005.02.2889

Duiker, 2006, The clinical trail of TRAIL, Eur J Cancer, 42, 2233, 10.1016/j.ejca.2006.03.018

Marini, 2006, Drug evaluation: Lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2, Curr Opin Mol Ther, 8, 539

Sun, 2006, Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic, J Med Chem, 49, 7916, 10.1021/jm061108d

McCubrey, 2006, Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance, Adv Enzyme Regul, 46, 249, 10.1016/j.advenzreg.2006.01.004

Clark, 2002, Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab or tamoxifen in breast cancer cells, Mol Cancer Ther, 1, 707

Liang, 2006, Differential roles of phosphoinositide-dependent protein kinase-1 and Akt1 expression and phosphorylation in breast cancer cell resistance to paclitaxel, doxorubicin, and gemcitabine, Mol Pharmacol, 70, 1045, 10.1124/mol.106.023333

Hu, 2002, Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models, Cancer Res, 62, 1087

O'Rourke, 2004, Targeted molecular therapy in glial tumors, Neurosurgery, 54, N9, 10.1227/01.NEU.0000309633.00854.FD

Lefranc, 2005, Possible future issues in the treatment of glioblastomas: Special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis, J Clin Oncol, 23, 2411, 10.1200/JCO.2005.03.089

Joy, 2003, Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis, J Cell Sci, 116, 4409, 10.1242/jcs.00712

Shingu, 2003, Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells, Cancer Res, 63, 4044

Cheung, 2004, Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells, Carcinogenesis, 25, 881, 10.1093/carcin/bgh087

McCormick, 2004, Cancer: Survival pathways meet their end, Nature, 428, 267, 10.1038/428267a

Bjornsti, 2004, The TOR pathway: A target for cancer therapy, Nat Rev Cancer, 4, 335, 10.1038/nrc1362

Reardon, 2006, Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma, Clin Cancer Res, 12, 860, 10.1158/1078-0432.CCR-05-2215

Ivanov, 2003, Death receptors and melanoma resistance to apoptosis, Oncogene, 22, 3152, 10.1038/sj.onc.1206456

Malhi, 2006, TRAIL resistance results in cancer progression: A TRAIL to perdition?, Oncogene, 25, 7333, 10.1038/sj.onc.1209765

Aggarwal, 2004, Nuclear factor-kappaB: The enemy within, Cancer Cell, 6, 203, 10.1016/j.ccr.2004.09.003

Reggiori, 2002, Autophagy in the eukaryotic cell, Eukaryot Cell, 1, 11, 10.1128/EC.01.1.11-21.2002

De Duve, 1966, Functions of lysosomes, Annu Rev Physiol, 28, 435, 10.1146/annurev.ph.28.030166.002251

Schweichel, 1973, The morphology of various types of cell death in prenatal tissues, Teratology, 7, 253, 10.1002/tera.1420070306

Lum, 2005, Growth factor regulation of autophagy and cell survival in the absence of apoptosis, Cell, 120, 237, 10.1016/j.cell.2004.11.046

Kanzawa, 2004, Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells, Cell Death Differ, 11, 448, 10.1038/sj.cdd.4401359

Kondo, 2005, The role of autophagy in cancer development and response to therapy, Nat Rev Cancer, 5, 726, 10.1038/nrc1692

Shintani, 2004, Autophagy in health and disease: A double-edged sword, Science, 306, 990, 10.1126/science.1099993

Lefranc, 2006, Autophagy, the Trojan horse to combat glioblastomas, Neurosurg Focus, 20, E7, 10.3171/foc.2006.20.4.4

Inbal, 2002, DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death, J Cell Biol, 157, 455, 10.1083/jcb.200109094

Lockshin, 2004, Apoptosis, autophagy and more, Int J Biochem Cell Biol, 36, 2405, 10.1016/j.biocel.2004.04.011

Pattingre, 2006, Bcl-2 inhibition of autophagy: A new route to cancer?, Cancer Res, 66, 2885, 10.1158/0008-5472.CAN-05-4412

Feng, 2005, The coordinate regulation of the p53 and mTOR pathways in cells, Proc Natl Acad Sci U S A, 102, 8204, 10.1073/pnas.0502857102

Jin, 2005, p53, autophagy and tumor suppression, Autophagy, 1, 171, 10.4161/auto.1.3.2051

Crighton, 2006, DRAM, a p53-induced modulator of autophagy, is critical for apoptosis, Cell, 126, 121, 10.1016/j.cell.2006.05.034

Gunn, 1977, Reduced rates of proteolysis in transformed cells, Nature, 266, 58, 10.1038/266058a0

Otsuka, 1978, Differences in the rates of protein degradation in untransformed and transformed cell lines, Exp Cell Res, 112, 127, 10.1016/0014-4827(78)90533-5

Liang, 1999, Induction of autophagy and inhibition of tumorigenesis by beclin1, Nature, 402, 672, 10.1038/45257

Aita, 1999, Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21, Genomics, 59, 59, 10.1006/geno.1999.5851

Miracco, 2007, Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumours, Int J Oncol, 30, 429

Chen, 1996, Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: Refining a putative tumor suppressor gene region, Cancer Res, 56, 5605

Elo, 1997, Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer, Cancer Res, 57, 3356

Suzuki, 2000, An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer, Cancer Res, 60, 5382

Miyakis, 2003, Absence of mutations in the VHL gene but frequent loss of heterozygosity at 3p25–26 in non-small cell lung carcinomas, Lung Cancer, 39, 273, 10.1016/S0169-5002(02)00506-8

Ogier-Denis, 2003, Autophagy: A barrier or an adaptive response to cancer, Biochim Biophys Acta, 1603, 113

Gozuacik, 2004, Autophagy as a cell death and tumor suppressor mechanism, Oncogene, 23, 2891, 10.1038/sj.onc.1207521

Eshleman, 2002, Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy, Cancer Res, 62, 7291

Paglin, 2001, A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles, Cancer Res, 61, 439

Kanzawa, 2005, Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3, Oncogene, 24, 980, 10.1038/sj.onc.1208095

Daido, 2004, Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells, Cancer Res, 64, 4286, 10.1158/0008-5472.CAN-03-3084

Gomez-Santos, 2003, Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells, J Neurosci Res, 73, 341, 10.1002/jnr.10663

Chau, 2003, Endostatin induces autophagic cell death in EAhy926 human endothelial cells, Histol Histopathol, 18, 715

Shao, 2004, Apoptotic and autophagic cell death induced by histone deacetylase inhibitors, Proc Natl Acad Sci U S A, 101, 18030, 10.1073/pnas.0408345102

Chen, 2005, Nano neodymium oxide induces massive vacuolization and autophagic cell death in non-small cell lung cancer NCI-H460 cells, Biochem Biophys Res Commun, 337, 52, 10.1016/j.bbrc.2005.09.018

Hoyer-Hansen, 2005, Vitamin D analog EB1089 triggers dramatic lysosomal changes and beclin 1-mediated autophagic cell death, Cell Death Differ, 12, 1297, 10.1038/sj.cdd.4401651

Ellington, 2005, Induction of macroautophagy in human colon cancer cells by soybean B-group triterpenoid saponins, Carcinogenesis, 26, 159, 10.1093/carcin/bgh297

Opipari, 2004, Resveratrol-induced autophagocytosis in ovarian cancer cells, Cancer Res, 64, 696, 10.1158/0008-5472.CAN-03-2404

Iwamaru, 2007, Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells, Oncogene, 26, 1840, 10.1038/sj.onc.1209992

Stupp, 2005, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330

Reardon, 2006, Therapeutic advances in the treatment of glioblastoma: Rationale and potential role of targeted agents, The Oncologist, 11, 152, 10.1634/theoncologist.11-2-152

Kanzawa, 2003, Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide, J Neurosurg, 99, 1047, 10.3171/jns.2003.99.6.1047

Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, 352, 997, 10.1056/NEJMoa043331

Roos, 2007, Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine, Oncogene, 26, 186, 10.1038/sj.onc.1209785

Maiuri, 2007, Self-eating and self-killing: Crosstalk between autophagy and apoptosis, Nat Rev Mol Cell Biol, 8, 741, 10.1038/nrm2239

Schilsky, 2002, End points in cancer clinical trials and the drug approval process, Clin Cancer Res, 8, 935

Nozawa, 2007, Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer, Cancer Lett, 251, 105, 10.1016/j.canlet.2006.11.008

Kim, 2006, Role of the unfolded protein response in cell death, Apoptosis, 11, 5, 10.1007/s10495-005-3088-0

Hori, 2004, Role of Herp in the endoplasmic reticulum stress response, Genes Cell, 9, 457, 10.1111/j.1356-9597.2004.00735.x

Kurisu, 2003, MDG1/ERdj4, an ER-resident DnaJ family member, suppresses cell death induced by ER stress, Genes Cells, 8, 189, 10.1046/j.1365-2443.2003.00625.x

Zhao, 2006, Endoplasmic reticulum stress in health and disease, Curr Opin Cell Biol, 18, 444, 10.1016/j.ceb.2006.06.005

Fu, 2006, Glucose regulated proteins in cancer progression, drug resistance and immunotherapy, Cancer Biol Ther, 5, 741, 10.4161/cbt.5.7.2970

Ranganathan, 2006, Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells, Cancer Res, 66, 1702, 10.1158/0008-5472.CAN-05-3092

Altieri, 2004, Coupling apoptosis resistance to the cellular stress response: The IAP-Hsp90 connection in cancer, Cell Cycle, 3, 255, 10.4161/cc.3.3.707

Fels, 2006, The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth, Cancer Biol Ther, 5, 723, 10.4161/cbt.5.7.2967

Park, 2004, Effect on tumor cells of blocking survival response to glucose deprivation, J Natl Cancer Inst, 96, 1300, 10.1093/jnci/djh243

Meli, 2006, Small-molecule targeting of heat shock protein 90 chaperone function: Rational identification of a new anticancer lead, J Med Chem, 49, 7721, 10.1021/jm060836y

Vastag, 2006, HSP-90 inhibitors promise to complement cancer therapies, Nat Biotechnol, 24, 1307, 10.1038/nbt1106-1307

Sharp, 2006, Inhibitors of the HSP90 molecular chaperone: Current status, Adv Cancer Res, 95, 323, 10.1016/S0065-230X(06)95009-X

Schmitt, 2006, Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma, Cancer Res, 66, 4191, 10.1158/0008-5472.CAN-05-3778